Cerebral dopamine neurotrophic factor - Herantis Pharma

Drug Profile

Cerebral dopamine neurotrophic factor - Herantis Pharma

Alternative Names: CDNF; CDNF-protein; HER-902

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Helsinki
  • Developer Herantis Pharma; Renishaw
  • Class Antiparkinsonians; Nerve growth factors
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase I/II Parkinson's disease
  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 27 Sep 2017 Phase-I/II clinical trials in Parkinson's disease in Finland (Intracerebral) (EudraCT-2015-004175-73)
  • 27 Sep 2017 Phase-I/II clinical trials in Parkinson's disease in Sweden (Intracerebral) (NCT03295786)
  • 01 Jun 2017 Finnish Medicines Agency approves IND application for Cerebral dopamine neurotrophic factor in Parkinson's disease in Finland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top